Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...

After financing itself for 12 years via high-net-worth individuals and Sosei, London-based MiNA has tapped a traditional VC to lead its series A round to expand its pipeline of small activating RNA therapeutics.  MiNA Therapeutics Ltd....

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...

AI and machine learning company insitro is looking to drug discovery as its next phase of platform development with an Andreessen Horowitz-led $143 million series B round. The company has spent the two years since...

Boehringer is showing itself to be a stealthy but serious player in cutting-edge science with the latest in a series of early-stage deals that come with little notice and plant a flag in an important...

There is broad agreement on the importance of creating policies to determine which countries will receive COVID-19 vaccines, but little concurrence on what those policies should be or how they will be created. On Wednesday,...

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...